ଫ୍ଲୁଟିକାସୋନ ଫୁରୋଏଟ/ଭିଲାଣ୍ଟେରୋଲ

ଫ୍ଲୁଟିକାସୋନ ଫୁରୋଏଟ/ଭିଲାଣ୍ଟେରୋଲ
Combination of
Fluticasone furoate	Corticosteroid
Vilanterol	Long-acting β2 agonist
Clinical data
Trade names	Breo Ellipta, Relvar Ellipta
AHFS/Drugs.com	entry
data	EU EMA: yes;
Routes of; administration	Inhalation
Legal status
Legal status	AU: S4 (Prescription only) ; UK: POM (Prescription only) ; US: ℞-only ; EU: Rx-only ; ℞ (Prescription only);

ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ବ୍ରେଓ ଏଲିପଟା ବ୍ରାଣ୍ଡ ନାମରେ ବିକ୍ରି ହେଉଥିବା ଫ୍ଲୁଟିକାସୋନ୍ ଫୁରୋଏଟ/ଭିଲାଣ୍ଟେରୋ ( FF / VI ) ହେଉଛି ଏକ ଔଷଧ ମିଶ୍ରଣ ଯାହା କ୍ରନିକ୍ ଅବଷ୍ଟ୍ରକ୍ଟିଭ୍ ଫୁସଫୁସ ରୋଗ (COPD) ଏବଂ ଆଜମା ରୋଗର ଦୀର୍ଘକାଳୀନ ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୪] ୟୁରୋପରେ ଏହା ଦ୍ୱିତୀୟ ଧାଡ଼ିର ଚିକିତ୍ସା ମାନ୍ୟତା ପାଇଛି ।^[୫] ଏହା ପାଟି ବାଟେ ପ୍ରଶ୍ୱାସ ନେଇ ବ୍ୟବହୃତ ହୁଏ ।^[୪]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ବିସ୍ଫୋଟକ ଦାଗ, ମୁଣ୍ଡବିନ୍ଧା, ଉପର ଶ୍ୱାସନଳୀ ସଂକ୍ରମଣ, କାଶ ଏବଂ ଗଳା ଯନ୍ତ୍ରଣା ହୋଇପାରେ ।^[୪] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ନିମୋନିଆ, ବ୍ରୋଙ୍କୋସ୍ପାଜ୍ମ, ଗ୍ଲକୋମା ଏବଂ କମ୍ ପୋଟାସିୟମ୍ ଅନ୍ତର୍ଭୁକ୍ତ ହୋଇପାରେ ।^[୪] ଏଥିରେ ଫ୍ଲୁଟିକାସୋନ ଫୁରୋଏଟ, କର୍ଟିକୋଷ୍ଟେରଏଡ୍ ଏବଂ ଭିଲାଣ୍ଟେରୋଲଯାହା ଏକ ଦୀର୍ଘକାଳୀନ କାର୍ଯ୍ୟ କରୁଥିବା β<sub>2</sub> ଆଗୋନିଷ୍ଟ (ଲାବା/ LABA) ଥାଏ | ^[୪] ବେଳେ ବେଳେ ଆଜମା ରୋଗର ଫଳାଫଳକୁ କେବଳ ଲାବା ଖରାପ କରିଦେଇପାରେ । ^[୪]

ଏହି ଔଷଧ ମିଶ୍ରଣକୁ ଆମେରିକା ଏବଂ ୟୁରୋପରେ ୨୦୧୩ ରେ ଚିକିତ୍ସା କ୍ଷେତ୍ରରେ ବ୍ୟବହାର ପାଇଁ ଅନୁମୋଦନ କରାଯାଇଥିଲା ।^[୪] ^[୨] ବୁଡେସୋନାଇଡ/ଫର୍ମୋଟରୋଲର ବିକଳ୍ପ ଭାବରେ ବିଶ୍ୱ ସ୍ୱାସ୍ଥ୍ୟ ସଂଗଠନର ଜରୁରୀ ଔଷଧ ତାଲିକାରେ ଏହାର ନାମ ଲିପିବଦ୍ଧ ଅଛି ।^[୬] ଏହା ଏକ ସାଧାରଣ ଔଷଧ ଭାବରେ ଉପଲବ୍ଧ ।^[୭] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୦୨୩ ମସିହା ସୁଦ୍ଧା ୬୦ ମାତ୍ରା ପାଇଁ ଏହାର ମୂଲ୍ୟ ୧୬୦ ଡଲାର ଥିଲା ।^[୭] ଯୁକ୍ତରାଜ୍ୟରେ ଏହାର ମୂଲ୍ୟ ପ୍ରାୟ ୪୪ ପାଉଣ୍ଡ ଥିଲା ।^[୮] ୨୦୨୦ ରେ, ଏହା ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୧୧୫ ତମ ସାଧାରଣ ଔଷଧ ଥିଲା ଯାହାର ୫ନିୟୁତରୁ ଅଧିକ ପ୍ରେସକ୍ରିପସନ୍ ଥିଲା ।^[୯] ^[୧୦]

ଆଧାର

↑ "Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 10 April 2023.
↑ ^୨.୦ ^୨.୧ "Relvar Ellipta EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 5 February 2020. Retrieved 23 March 2021.
↑ "Relvar Ellipta 92 micrograms/22 micrograms inhalation powder, pre-dispensed - Summary of Product Characteristics (SmPC)". (emc). 7 December 2020. Archived from the original on 5 February 2020. Retrieved 23 March 2021.
↑ ^୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ ^୪.୫ ^୪.୬ ^୪.୭ "Breo Ellipta- fluticasone furoate and vilanterol trifenatate powder". DailyMed. Archived from the original on 26 May 2020. Retrieved 23 March 2021.
↑ "Summary of opinion: Relvar Ellipta" (PDF). European Medicines Agency. 19 September 2013. Archived (PDF) from the original on 24 September 2015. Retrieved 28 May 2023.
↑ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
↑ ^୭.୦ ^୭.୧ "Generic Breo Ellipta". GoodRx. Archived from the original on 25 April 2020. Retrieved 9 September 2023.
↑ "Fluticasone with vilanterol Medicinal forms". NICE. Archived from the original on 10 September 2023. Retrieved 9 September 2023.
↑ "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 7 October 2022.
↑ "Fluticasone; Vilanterol - Drug Usage Statistics". ClinCalc. Archived from the original on 10 October 2022. Retrieved 7 October 2022.

[1] "Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 10 April 2023.

[EPAR2023-2] ୨.୦ ^୨.୧ "Relvar Ellipta EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 5 February 2020. Retrieved 23 March 2021.

[3] "Relvar Ellipta 92 micrograms/22 micrograms inhalation powder, pre-dispensed - Summary of Product Characteristics (SmPC)". (emc). 7 December 2020. Archived from the original on 5 February 2020. Retrieved 23 March 2021.

[PI2023-4] ୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ ^୪.୫ ^୪.୬ ^୪.୭ "Breo Ellipta- fluticasone furoate and vilanterol trifenatate powder". DailyMed. Archived from the original on 26 May 2020. Retrieved 23 March 2021.

[5] "Summary of opinion: Relvar Ellipta" (PDF). European Medicines Agency. 19 September 2013. Archived (PDF) from the original on 24 September 2015. Retrieved 28 May 2023.

[WHO23rd-6] World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.

[GX2023-7] ୭.୦ ^୭.୧ "Generic Breo Ellipta". GoodRx. Archived from the original on 25 April 2020. Retrieved 9 September 2023.

[8] "Fluticasone with vilanterol Medicinal forms". NICE. Archived from the original on 10 September 2023. Retrieved 9 September 2023.

[9] "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 7 October 2022.

[10] "Fluticasone; Vilanterol - Drug Usage Statistics". ClinCalc. Archived from the original on 10 October 2022. Retrieved 7 October 2022.

[୪]

[୫]

[୧]

[୩]

[୨]

[୬]

[୭]

[୮]

[୯]

[୧୦]